Skip to main content

Table 2 Univariate analysis of factors predicting recurrence-free and overall survival

From: Overexpression of a panel of cancer stem cell markers enhances the predictive capability of the progression and recurrence in the early stage cholangiocarcinoma

VariableMedian RFS (months)Recurrence-free survivalMedian
OS (months)
Overall survival
HRP (95% CI)HRP (95% CI)
Overall15.0  17.0  
Sex
 Female13.010.336 (0.853–1.593)16.910.270 (0.872–1.634)
 Male15.01.16617.41.193
Age (year)
 Less than 6116.010.208 (0.899–1.630)19.210.032 (1.028–1.876)
 61 or greater13.01.21116.31.388
Tumor site
 Intrahepatic12.510.449 (0.664–1.199)16.010.560 (0.680–1.232)
 Extrahepatic16.00.89218.50.915
Histology type
 Papillary16.010.253 (0.884–1.599)17.610.759 (0.779–1.409)
 Others13.01.18916.31.047
Primary tumor (T)
 I, II18.01< 0.001 (1.956–3.771)22.01< 0.001 (1.907–3.629)
 III, IV9.02.71611.02.630
Reginal lymph nodes (N) metastasis
 No17.010.001 (1.265–2.362)20.01< 0.001 (1.442–2.704)
 Yes10.51.72913.01.975
Distant metastasis (M)
 No15.010.762 (0.432–3.150)17.010.519 (0.513–3.751)
 Yes12.01.16613.51.387
TNM stage
 I, II18.01< 0.001 (1.576–2.986)21.61< 0.001 (1.711–3.255)
 III, IV10.02.16912.82.360
Post-operative CMT
 No15.010.933 (0.727–1.340)16.910.556 (0.671–1.239)
 Yes15.00.98719.00.912
CD44
 Low18.01 0.007 (1.129–2.170)22.01 0.001 (1.250–2.399)
 High13.01.56516.11.732 
CD44v6
 Neg.17.010.001 (1.234–2.311)19.210.006 (1.128–2.081)
 Pos.11.01.68912.81.532
CD44v8-10
 Neg.16.0 10.007 (1.125–2.072)20.01< 0.001 (1.271–2.352)
 Pos.13.01.52714.11.729
CD133
 Neg.16.010.103 (0.949–1.765)18.110.083 (0.965–1.794)
 Pos.12.51.29516.11.316
EpCAM
  Low14.010.135 (0.594–1.073)16.310.261 (0.629–1.134)
 High16.00.79818.60.844
ALDH1A1
 Low11.010.075 (0.569–1.028)16.010.022 (0.525–0.950)
 High17.00.76519.90.706
  1. TNM primary tumor-node-metastasis, post-operative, CMT post-operative chemotherapeutic treatment, HR hazard ratio, 95% CI 95% confidence interval, CD44 cluster of differentiation 44, CD44v CD44 variant, CD133 cluster of differentiation 133, EpCAM epithelial cell adhesion molecules, ALDH1A1 aldehyde dehydrogenase 1A1, TNM primary tumor-node-metastasis, Neg negative expression, Pos positive expression